EGFR and neoplasm: A recent publication from our collaborators shows that EGFR nonshedders have smaller baseline tumour target lesion size39, being in line with our observation that this cohort has the least number of detectable genomic alterations and the lowest VAFs of these mutations (Supplementary Fig. 2b, c).